Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: J Immunol. 2020 Jan 17;204(5):1386–1394. doi: 10.4049/jimmunol.1900742

Figure 4. Checkpoint blockade combined with CMP-001 enhances therapy via T cell dependent anti-tumor responses.

Figure 4.

A-B,Treatment schema and Kaplan-Meier curves of Balb/c mice primed and then implanted on both flanks with A20 B lymphoma cells, followed by unilateral IT CMP-001 or saline and IP anti-PD-1 mAb or isotype control (data is from 4 replicate experiments; n=32–38 mice per group). C-D, Treatment schema and Kaplan-Meier curves of Balb/c mice primed and then implanted on both flanks with A20 B lymphoma cells, followed by unilateral IT CMP-001 and IP anti-PD-1 mAb, with and without T cell depletion (+ depleting antibody or isotype control). All depleting or isotype control antibodies were administered starting 2 days prior to the first IT/IP treatment and continued per treatment schedule. E, Tumor volumes (red=injected and black=noninjected) of individual mice after bilateral tumor implantation and combination treatment with CD4, CD8 or CD4 and CD8 T cell depleting antibodies (D-E: data is representative of 2 replicate experiments; n=9–10 mice per group). Survival data were analyzed using the Logrank test.